BioCentury
ARTICLE | Distillery Therapeutics

Cardiovascular

February 13, 2018 4:50 PM UTC

Patient sample, rat and mouse studies suggest inhibiting HDAC2 could help treat diastolic dysfunction. In postmortem myofibrils from heart failure patients, diastolic relaxation time was longer than in matched samples from unaffected donors, and in ex vivo myofibrils from a rat model of hypertension-induced diastolic dysfunction, HDAC2 increased the duration of relaxation time compared with no treatment. In the rat model and in a mouse model of age-related diastolic dysfunction, the HDAC inhibitor givinostat decreased diastolic relaxation time compared with vehicle or no treatment, respectively. Next steps could include testing HDAC2-specific inhibitors in models of diastolic dysfunction.

Italfarmaco S.p.A. has givinostat in Phase II/III and Phase III testing for Duchenne muscular dystrophy (DMD) and Phase II testing for Becker muscular dystrophy and myeloproliferative neoplasms...

BCIQ Target Profiles

HDAC